Literature DB >> 16013781

Acquisition of drug resistance in multidrug-resistant Mycobacterium tuberculosis during directly observed empiric retreatment with standardized regimens.

L L Han1, A Sloutsky, R Canales, V Naroditskaya, S S Shin, K J Seung, R Timperi, M C Becerra.   

Abstract

The risk of acquiring additional drug resistance in strains of multidrug-resistant tuberculosis (MDR-TB) during failure of empiric standardized retreatment regimens is poorly defined. We sought to estimate this risk by comparing drug susceptibility profiles and RFLP patterns of paired MDR-TB isolates collected from 27 patients before and after retreatment failure. Among 23 patients with paired isolates with concordant RFLP patterns, 19 (83%) had become resistant to at least one additional drug after failed retreatment. In this limited group of MDR-TB patients, acquisition of resistance was common during failure of empiric drug regimens. Further study is needed to confirm these findings.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16013781

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  14 in total

Review 1.  The emergence of extensively drug-resistant tuberculosis: a global health crisis requiring new interventions: Part II: scientific advances that may provide solutions.

Authors:  Jerrold J Ellner
Journal:  Clin Transl Sci       Date:  2009-02       Impact factor: 4.689

Review 2.  The emergence of extensively drug-resistant tuberculosis: a global health crisis requiring new interventions: part I: the origins and nature of the problem.

Authors:  Jerrold J Ellner
Journal:  Clin Transl Sci       Date:  2008-12       Impact factor: 4.689

3.  Antituberculosis drug resistance acquired during treatment: an analysis of cases reported in California, 1994-2006.

Authors:  Travis C Porco; Peter Oh; Jennifer M Flood
Journal:  Clin Infect Dis       Date:  2012-12-07       Impact factor: 9.079

4.  Aggressive regimens for multidrug-resistant tuberculosis reduce recurrence.

Authors:  Molly F Franke; Sasha C Appleton; Carole D Mitnick; Jennifer J Furin; Jaime Bayona; Katiuska Chalco; Sonya Shin; Megan Murray; Mercedes C Becerra
Journal:  Clin Infect Dis       Date:  2012-12-07       Impact factor: 9.079

Review 5.  Epidemiology and treatment of multidrug resistant tuberculosis.

Authors:  Carole D Mitnick; Sasha C Appleton; Sonya S Shin
Journal:  Semin Respir Crit Care Med       Date:  2008-09-22       Impact factor: 3.119

6.  Drug-susceptibility patterns of Mycobacterium tuberculosis in Mpumalanga province, South Africa: possible guiding design of retreatment regimen.

Authors:  E Green; C L Obi; M Nchabeleng; B E de Villiers; P P Sein; T Letsoalo; A A Hoosen; P O Bessong; R N Ndip
Journal:  J Health Popul Nutr       Date:  2010-02       Impact factor: 2.000

7.  Acquired resistance to second-line drugs among persons with tuberculosis in the United States.

Authors:  Julia V Ershova; Ekaterina V Kurbatova; Patrick K Moonan; J Peter Cegielski
Journal:  Clin Infect Dis       Date:  2012-08-31       Impact factor: 9.079

8.  On the spread and control of MDR-TB epidemics: an examination of trends in anti-tuberculosis drug resistance surveillance data.

Authors:  Ted Cohen; Helen E Jenkins; Chunling Lu; Megan McLaughlin; Katherine Floyd; Matteo Zignol
Journal:  Drug Resist Updat       Date:  2014-10-06       Impact factor: 18.500

9.  Multiple introductions of multidrug-resistant tuberculosis into households, Lima, Peru.

Authors:  Ted Cohen; Megan Murray; Ibrahim Abubakar; Zibiao Zhang; Alexander Sloutsky; Fernando Arteaga; Katiuska Chalco; Molly F Franke; Mercedes C Becerra
Journal:  Emerg Infect Dis       Date:  2011-06       Impact factor: 6.883

10.  Multidrug-Resistant Tuberculosis in Patients for Whom First-Line Treatment Failed, Mongolia, 2010-2011.

Authors:  Claudia C Dobler; Sarah Korver; Ochirbat Batbayar; Batiargal Nyamdulam; Sodnomdarjaa Oyuntsetseg; Bold Tsolmon; Bazarragchaa Surmaajav; Byambaa Bayarjargal; Ben J Marais
Journal:  Emerg Infect Dis       Date:  2015-08       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.